Peter Attia· MD
and the same is true on LDL I do want to follow up on that point yes yes yes we absolutely will because it's such an important point and to me it's one of the two most interesting clinical assays I'd like to see developed I would love to see a clinical assay for a possi 3 & 4 LDL triglyceride concentration which goes back to a point we had a few minutes ago and for anybody listening who's developing this a please reach out to me because for all the self experimentation I do I mean one of the things I didn't mention is that I literally just did my hundredth blood draw last Tuesday I've obviously done enormous amounts of self testing to do this and that's exactly one of the things I want to check is how dynamic or not dynamic the distribution of things like a Bo c3 are based on for example existing illness or the energy distribution of so forth so anyway I realize we're kind of getting in the weeds here that means you should have a low level of c3 because your insulin levels are quite low so c3 tends to move with insulin so this right may be one of the things that explains why someone with type 2 diabetes who is hyperinsulinemic will on a particle for particle basis maybe even have a greater burden of the lipoprotein because the actual residence time of each of their particles both the LDL and LDL is longer than someone with lower insulin